Cargando…

PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study

BACKGROUND: Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for third-line treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has been proven effective in advanced GC/EGJC. Numero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Qing, Yuan, Xing, Li, Jingjing, Xu, Qi, Ying, Jieer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798944/ https://www.ncbi.nlm.nih.gov/pubmed/35117897 http://dx.doi.org/10.21037/tcr-20-1333

Ejemplares similares

Correlation Between Hemoglobin Levels and the Prognosis of First-Line Chemotherapy in Patients with Advanced Gastric Cancer
por: Wei, Qing, et al.
Publicado: (2020)

Advanced esophagogastric junction cancer with brain, bone and gastric intramural metastases responding to combined modality therapy
por: Takagi, Takehiro, et al.
Publicado: (2021)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction
por: Cai, Ming-Zhi, et al.
Publicado: (2019)

Oncologic Feasibility of Proximal Gastrectomy in Upper Third Advanced Gastric and Esophagogastric Junctional Cancer
por: Yun, Won-Gun, et al.
Publicado: (2021)

Organotypic slice cultures of human gastric and esophagogastric junction cancer
por: Koerfer, Justus, et al.
Publicado: (2016)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan
por: Yoshida, Tsutomu, et al.
Publicado: (2022)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study
por: Xu, Haitao, et al.
Publicado: (2020)

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
por: Zeng, Hui, et al.
Publicado: (2023)

Can proximal Gastrectomy Be Justified for Advanced Adenocarcinoma of the Esophagogastric Junction?
por: Sato, Yuya, et al.
Publicado: (2018)

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction
por: Zheng, Yi-Han, et al.
Publicado: (2022)

Comment on case report on mini-gastric bypass and esophagogastric junction carcinoma
por: Tolone, Salvatore, et al.
Publicado: (2020)

Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study
por: Imamura, Yu, et al.
Publicado: (2020)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
por: Ju, Wu-tong, et al.
Publicado: (2022)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
por: Liu, Bo-Wei, et al.
Publicado: (2023)

Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy
por: Luo, Cong, et al.
Publicado: (2017)

Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
por: Li, Shengli, et al.
Publicado: (2023)

Surgical resection of gastric stump cancer following proximal gastrectomy for adenocarcinoma of the esophagogastric junction
por: Ma, Fu-Hai, et al.
Publicado: (2019)

Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
por: Xu, Jianming, et al.
Publicado: (2020)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Changes of Quality of Life after Gastric Tube Reconstruction in Adenocarcinoma of the Esophagogastric Junction
por: Shen, Chaoyong, et al.
Publicado: (2013)

Intragastric Endoscopic Assisted Single Incision Surgery for Gastric Leiomyoma of the Esophagogastric Junction
por: Morales-Conde, Salvador, et al.
Publicado: (2013)

Current status of proximal gastrectomy for gastric and esophagogastric junctional cancer: A review
por: Nunobe, Souya, et al.
Publicado: (2020)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study
por: Xia, Wei-Li, et al.
Publicado: (2022)

Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
por: Li, Li-Hua, et al.
Publicado: (2022)

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma
por: Xu, Yi-Wei, et al.
Publicado: (2018)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Xia, Wei-Li, et al.
Publicado: (2023)

Self-expandable metal stent of esophagogastric junction versus pyloric area obstruction in advanced gastric cancer patients: Retrospective, comparative, single-center study
por: Kim, Deok Yeong, et al.
Publicado: (2020)

RISK FACTORS FOR SEVERE POSTOPERATIVE COMPLICATIONS AFTER GASTRECTOMY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION CANCERS
por: NORERO, Enrique, et al.
Publicado: (2019)

Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer
por: Yanagimoto, Yoshitomo, et al.
Publicado: (2023)

Esophageal Stent for Cervical Esophagus and Esophagogastric Junction
por: Shim, Chan Sup
Publicado: (2012)

Current surgical treatment of esophagogastric junction adenocarcinoma
por: Zhang, Shun, et al.
Publicado: (2019)

Esophagogastric Junction Outflow Obstruction Caused by Gabapentin
por: Barret, Maximilien, et al.
Publicado: (2019)

The combination of preoperative fibrinogen and neutrophil-lymphocyte ratio is a predictive prognostic factor in esophagogastric junction and upper gastric cancer
por: Cong, Xiliang, et al.
Publicado: (2019)

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
por: Yuan, Zhen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c5lcbmkk3uq5ba3smfag05q36o